For research use only. We do not sell to patients.
Ionizable lipids / ssPalmO-Phe
ssPalmO-Phe chemical structure
Product imageResearch use only
CAT. NO. DC59002Featured

ssPalmO-Phe

Pack size & price

USD
Supporting components
Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$600
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

ssPalmO-Phe is a self-degradable ionizable lipid-like material studied for hepatic delivery of siRNA and antisense oligonucleotides. The reported siRNA and ASO formulations differ in composition and loading. Strong knockdown was accompanied by cargo-dependent liver toxicity in the ASO experiments.

Open full Formulation & Performance →

Literature evidence · DC59002

Formulation & Performance

This review distinguishes siRNA potency, ASO potency, particle recovery and encapsulation, and the safety of loaded versus empty particles.

The results below describe the cited research formulations. Product specifications and commercial pack options are shown in the Specifications and ordering sections.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
ssPalmO-PheDC590021173.777700.809501
CholesterolDCD-041386.65300.114281
DMG-PEG2000DC4016925071.50.037049

siRNA formulation: ssPalmO-Phe/cholesterol = 70:30 with an additional 1.5 parts DMG-PEG2000; lipid/siRNA = 400 nmol/µg. The displayed 70:30:1.5 parts are normalized only for mass calculations. The 400 nmol/µg value is neither a weight ratio nor N/P. ASO uses the separate four-component composition below.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
ssPalmO-Phe——
Cholesterol——
DMG-PEG2000——

Separate ASO formulation and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
ssPalmO-PheDC590021173.777400.462572
DOPCDC33653786.11200.154899
CholesterolDCD-041386.65400.152374
DMG-PEG2000DC4016925071.50.037049

ssPalmO-Phe/DOPC/cholesterol = 40:20:40 plus 1.5 parts DMG-PEG2000. Lipid/ASO = 25 nmol/µg. The sum of the displayed parts is 101.5; this is not the siRNA composition. Main text Section 3.5 and Table 3.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
ssPalmO-Phe——
DOPC——
Cholesterol——
DMG-PEG2000——

siRNA particle properties and loading

PreparationMeasured propertiesSource / distinction
1.5% PEG addition, siRNA formulation112 nm; PDI 0.135; zeta potential −4.6 mVMain Table 1.
Same preparation64% siRNA recovery; 100% encapsulation efficiencyRecovery is the fraction of input recovered; encapsulation is a different measurement.
3% PEG head-group comparison96 nm; PDI 0.079; zeta potential −6 mV; 46% recovery; 100% encapsulationMain Table 2; a distinct preparation, not the 1.5% PEG row.
Surface pKa5.97 ± 0.06Main Fig. 6b; head-group comparison context.

Hepatic siRNA knockdown

Model / endpointDose / timingResult
Mouse plasma factor VIIIV siRNA; 24 h; n = 3ED50 = 4.4 µg/kg (Main Fig. 4).
Higher tested dose40 µg/kg siRNA; 24 h98.7 ± 1.3% factor VII knockdown (Main Fig. 4).

These results belong to the optimized siRNA formulation, not the ASO formulation.

ASO particle properties

CargoDiameter / PDI / zeta potentialLoading measurement
ApoB-targeting ASO (ASOap)45 nm / 0.156 / −2.6 mV24.1% recovery; Table 3.
Nr3c1-targeting ASO (ASOgr)53 nm / 0.185 / +12 mV71.4% recovery; Table 3.
ASO encapsulation efficiencyNot reliably quantifiedThe authors report that the OliGreen assay without surfactant did not yield reliable fluorescence; recovery is not substituted for encapsulation.

ASO liver knockdown

Cargo / targetLNP versus naked ASOStudy context
ASOap / ApoBIC50 0.0097 versus 1.41 mg/kg; 146-fold dose differenceIV; liver gene expression at 96 h; n = 4; Main Fig. 8a.
ASOgr / Nr3c1IC50 0.092 versus 3.61 mg/kg; 39.3-fold dose differenceIV; liver gene expression at 96 h; n = 4; Main Fig. 8b.

Cargo-dependent tolerability

ExperimentFindingInterpretation
ASOap-loaded LNPSevere hepatotoxicity at the 0.37 mg/kg ASO doseMain Fig. 9. Potency improvements did not eliminate ASO-associated liver injury.
ASOgr-loaded LNPAST/ALT elevations were also observed at 0.37 mg/kg, with lower magnitude than ASOapMain Fig. 9b; both ASO-loaded formulations reveal toxicity at lower doses than the naked-ASO comparators.
Empty ASO-composition LNPNo significant AST/ALT elevation reported over 49–782 mg/kg total lipid (29–470 mg/kg ssPalmO-Phe), at 96 hMain Fig. 10. This is not evidence that loaded LNPs are safe over that range.
Other formulation contextThe discussion cites liver-enzyme elevation at high doses for a different mRNA compositionSafety depends on composition, cargo, dose and observation window; empty-particle results cannot be generalized.

Original study figures

Figure 4 · siRNA factor VII knockdown
Figure 4 · siRNA factor VII knockdown
Tanaka et al., Pharmaceutics (2021), Figure 4. Original, unmodified figure; factor VII knockdown in mice. CC BY 4.0. Original source and caption · CC BY 4.0
Figure 8 · ApoB and Nr3c1 ASO knockdown
Figure 8 · ApoB and Nr3c1 ASO knockdown
Tanaka et al., Pharmaceutics (2021), Figure 8. Original, unmodified figure; LNP versus naked ASO hepatic knockdown. CC BY 4.0. Original source and caption · CC BY 4.0
Figure 9 · ASO-associated liver toxicity
Figure 9 · ASO-associated liver toxicity
Tanaka et al., Pharmaceutics (2021), Figure 9. Original, unmodified figure; liver injury endpoints must be read alongside efficacy. CC BY 4.0. Original source and caption · CC BY 4.0

References and source locations

  1. Tanaka H, et al. Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material. Pharmaceutics 13, 544 (2021). DOI: 10.3390/pharmaceutics13040544.
  2. Full text: Tables 1–3 and Figures 4, 6, 8–10; supplementary serum/hemolysis data.
CAS No.2377474-67-2
Chemical NamessPalmO-Phe
SynonymsBenzeneacetic acid, 4-[[(9Z )-1-oxo-9-octadecen-1-yl]oxy]-, 1,1′-[dithiobis(2,1-ethanediyl-1,4-piperidinediyl-2,1-ethanediyl)] ester (ACI);ssPalmOPhe， ssPalmO Phe
SMILESC(C(OCCC1CCN(CCSSCCN2CCC(CCOC(CC3=CC=C(OC(CCCCCCC/C=C\CCCCCCCC)=O)C=C3)=O)CC2)CC1)=O)C4=CC=C(OC(CCCCCCC/C= C\CCCCCCCC)=O)C=C4
FormulaC70H112N2O8S2
M.Wt1173.777
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Tanaka H, et al. Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material. Pharmaceutics 13, 544 (2021). DOI: 10.3390/pharmaceutics13040544.
  2. Full text: Tables 1–3 and Figures 4, 6, 8–10; supplementary serum/hemolysis data.
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

The paper reports 70/30 plus an additional 1.5 mol% DMG-PEG2000 (sum 101.5). The calculator retains those raw ratios and normalizes them only for lipid-component weighing. RNA, buffer, solvent, process loss and the 400 nmol/microgram loading are not included.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg8.5195 mL1.7039 mL851.95 μL
25 mg21.2988 mL4.2598 mL2.1299 mL
50 mg42.5975 mL8.5195 mL4.2598 mL
100 mg85.1951 mL17.0390 mL8.5195 mL
250 mg212.9876 mL42.5975 mL21.2988 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.